A Phase 3, Multicenter, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Subjects From 2 to 18 Years in Taiwan
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2014
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Pharmacodynamics; Registrational
- Sponsors Novartis
- 06 Sep 2012 Actual initiation date changed from Mar 2012 to Jan 2012 as reported by ClinicalTrials.gov.
- 12 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Mar 2012 Actual patient number (341) added as reported by ClinicalTrials.gov.